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INTRODUCTION 
 
Background: ICU patients often receive glycaemic control to 
mitigate the negative effects of prolonged hyperglycemia. However, 
results of glycaemic control protocols have been mixed. Quality 
and consistency can be variable, leading to sub-optimal outcomes 
due to both patient-specific and external factors. In particular, 
intensive insulin therapy can lead to risk of iatrogenic 
hypoglycemia. 
  
Objective: To report initial clinical results of the STAR glycaemic 
control protocol at an independent intensive care unit (ICU) in 
comparison to its first implementation. 
CONCLUSIONS 
 
STAR was equally effective in two ICUs, across geographically distinct clinical 
units, patients, and clinical practice. No significant difference was seen using 
infusion or bolus insulin. The STAR framework was readily transposed and 
quality glycaemic control was achieved. 
METHODS 
 
15 pilot episodes (1168 hours) using STAR at Kálmán Pándy 
Hospital (Gyula, Hungary) are directly compared to 38 episodes 
(3763 hours) in Christchurch Hospital. Only patients with a target 
range of 4.4 - 8.0 mmol/L were included. Performance is assessed 
by percentage of (hourly re-sampled) BG measurements in 
glycaemic bands. Safety is assessed by numbers of patients with 
severe hypoglycaemia (BG < 2.2mmol/L) and degree of mild 
hypoglycaemia (%BG<4.0mmol/L). Clinical effort is assessed as 
average BG measurements per day. 
 
Gyula administers insulin as constant infusions, and STAR actively 
controls both enteral and parenteral nutrition inputs. Christchurch 
uses insulin boluses, and STAR actively controls enteral nutrition 
(parenteral nutrition is clinically determined). Measurements were 
1-3-hourly, with available intervals determined by STAR, and 
chosen by nursing staff. 
 
STAR determines optimal combinations of nutrition and insulin by 
identifying patient-specific insulin sensitivity (SI), and using 
stochastic forecasting to predict how patient condition is likely to 
change over the next 1-3 hours. 
RESULTS 
 
STAR was able to target BG to an equivalent level in two distinct ICUs, with 
cohort BG at 6.0 [5.4 - 6.8] mmol/L (Gyula) and 6.1 [5.6 - 6.8] mmol/L 
(Christchurch). Effort was similar (12.3 and 12.8 measurements/day in Gyula and 
Christchurch, respectively).  
 
Gyula performance/safety: 72.7% and 80.43% of BG in 4.4-7.0 and 4.4-
8.0mmol/L bands and 2.2% BG<4.0mmol/L. Christchurch performance/safety: 
77.8% and 89.43% of BG in the 4.4-7.0 and 4.4-8.0mmol/L bands and 0.87% 
BG<4.0mmol/L. There were no severe hypoglycemic events during STAR in either 
ICU.  
 
Performance differences were due to 1 Gyula patient without whom all metrics 
were within 0.1-1.0% difference. Insulin and nutrition inputs were comparable, 
with Gyula patients receiving increased nutrition inputs due to clinical practice. 
 
BG distributions in Christchurch were markedly similar to those predicted by 
virtual trials. 
Figure 1a - above: A schematic of the ICING model used 
to generate BG predictions with STAR.  
 
Figure 1b - left: STAR is run on a tablet by the bedside 
(pictured). 
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
Blood Glucose (mmol/L)
C
u
m
u
la
ti
v
e
 D
e
n
s
it
y
 (
%
)
Comparison of Virtual and Pilot Trial Results, Christchurch
 
 
Predicted (Virtual Trials), N=371
STAR Christchurch, N=38
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
Blood Glucose (mmol/L)
STAR Multi-Centre Comparison
 
 
STAR Christchurch, N=38
STAR Gyula, N=15
STAR Gyula (Excluded outlier), N=14
Figure 2: BG cumulative density functions from Christchurch Pilot trial and virtual trials using the N=371 SPRINT cohort (LHS). 
These two curves are remarkably similar, showing good agreement between the predicted and observed results in a single ICU. 
BG distributions from STAR Christchurch and Gyula are overlaid (RHS), showing the transferability of the STAR protocol. 
Removal of a single outlier patient makes a dramatic difference to Gyula results. 
Christchurch Gyula 
Patients 
Number of episodes 38 15 
Hours of control 3763 1168 
Workload 
# BG measurements: 1948 622 
Measures/day: 12.4 12.8 
Control performance 
BG median [IQR] (mmol/L): 6.1 [5.6 - 6.8] 6.0 [5.4 - 6.8] 
% BG within 4.4 – 7.0 mmol/L 77.8 72.7 
% BG within 4.4 – 8.0 mmol/L 89.4 80.4 
% BG within 8.0 – 10.0 mmol/L 6.1 10.0 
% BG > 10.0 mmol/L 3.0 2.2 
Safety 
% BG < 4.4 mmol/L 1.54 4.85 
% BG < 4.0 mmol/L 0.87 2.43 
% BG < 2.2 mmol/L 0.0 0.0 
# patients < 2.2 mmol/L 0 0 
Clinical interventions 
Median insulin rate [IQR] (U/hr): 3.0 [1.5 - 4.5] 2.5 [1.0 - 4.5] 
Median [IQR] enteral nutrition rate (g of carb/hr): 4.9 [0.0 - 6.1] 4.4 [2.4 - 5.5] 
Median [IQR] parenteral nutrition rate (g of carb/hr): 0.0 [0.0 - 0.0] 3.4 [1.6- 4.2] 
Table 1: Summary table of results from the clinical trial. Overall, the results show high control performance and low clinical effort, 
with safety preserved and no patients experiencing episodes of severe hyperglycemia. 
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